Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901033 | 0.86 | ACE (0.66) | ACELTA4H | |
| SCHEMBL6435304 | 0.86 | ACE (0.65) | ACELMNALTA4H | |
| SCHEMBL6435307 | 0.86 | ACE (0.65) | ACELMNALTA4H | |
| SCHEMBL13111774 | 0.81 | ACE (0.80) | ACELMNASMN1; SMN2 | |
| SCHEMBL9554734 | 0.81 | ACE (0.81) | ACELTA4H | |
| SCHEMBL9554742 | 0.81 | ACE (0.81) | ACELTA4H | |
| SCHEMBL22702314 | 0.81 | ACE (0.76) | ACELMNASMN1; SMN2 | |
| SCHEMBL6787624 | 0.80 | ACE (0.76) | ACELTA4H | |
| SCHEMBL6787617 | 0.80 | ACE (0.76) | ACELTA4H | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 0.79 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | ACE 39/4885LMNA 3478/4885LTA4H 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.